IP Library › Granted Patent US 7,923,449
Granted Patent B2
US 7,923,449 · App. 12/091,848 · Granted Apr 12, 2011

Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,923,449
App. No.
12/091,848
Granted
Apr 12, 2011
Kind
B2
Abstract

The invention relates to the use of benzimidazolone derivatives of formula (I) for the preparation of a medicament for the treatment of premenstrual and other female sexual disorders.

Claims (21)

1. A method of treating a premenstrual disorder comprising administering to an individual a therapeutically effective amount of a compound of formula (I)

wherein R 1 , R 2 , R 3 , and R 4 denote hydrogen or hydroxyl, with the proviso that R 1 , R 2 , R 3 , and R 4 cannot simultaneously represent hydrogen, or a pharmacologically acceptable acid addition salt thereof, to treat the premenstrual disorder.

2. The method according to claim 1 , wherein the premenstrual disorder comprises premenstrual dysphoria, premenstrual syndrome, or premenstrual dysphoric disorder.

3. The method according to claim 1 , wherein the compound of formula (I) is administered as a pharmaceutically acceptable acid addition salt formed by an acid comprising maleic, citric, tartaric, methanesulphonic, acetic, benzoic, succinic, gluconic, isethionic, glycinic, lactic, malic, mucoic, glutamic, sulphamic, ascorbic, hydrochloric, hydrobromic, nitric, sulfuric, phosphoric, or mixtures thereof.

4. The method according to claim 1 , wherein the compound of formula (I) is administered in a dosage range between 0.1 and 400 mg per day.

5. The method according to claim 1 , wherein the compound of formula (I) is compound (I.a)

or a pharmacologically acceptable acid addition salt thereof.

6. The method according to claim 1 , wherein the compound of formula (I) is compound (I.b)

or a pharmacologically acceptable acid addition salt thereof.

7. The method according to claim 1 , wherein the compound of formula (I) is compound (I.c)

or a pharmacologically acceptable acid addition salt thereof.

8. The method according to claim 1 , wherein the compound of formula (I) is compound (I.d)

or a pharmacologically acceptable acid addition salt thereof.

9. The method according to claim 1 , wherein the compound of formula (I) is compound (I.c)

or a pharmacologically acceptable acid addition salt thereof.

10. The method according to claim 1 , wherein the compound of formula (I) is compound (I.f)

or a pharmacologically acceptable acid addition salt thereof.

11. The method according to claim 1 , wherein the compound of formula (I) is compound (I.g)

or a pharmacologically acceptable acid addition salt thereof.

12. The method according to claim 1 , wherein the compound of formula (I) is compound (I.h)

or a pharmacologically acceptable acid addition salt thereof.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: THE BANK OF NEW YORK MELLON
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0236 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: BARCLAYS BANK PLC
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0194 →
SECURITY INTEREST Recorded Feb 25, 2021
From: SPROUT PHARMACEUTICALS, INC.
To: GOODRICH, BRAXTON; WHITEHEAD, ROBERT
Reel/Frame 055407/0810 →
SECURITY INTEREST Recorded Jul 19, 2017
From: SPROUT PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0950 →
SECURITY AGREEMENT Recorded Dec 21, 2015
From: SPROUT PHARMACEUTICALS, INC., AS GRANTOR; UNILENS VISION INC., AS GRANTOR; COMMONWEALTH LABORATORIES, LLC, AS GRANTOR; SYNERGETICS USA, INC., AS GRANTOR
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 037357/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2012
From: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 027705/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2008
From: CECI, ANGELO
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 021688/0953 →